HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TMDX

TransMedics Group, Inc. (Russell 2000)

Healthcare — Medical Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Buy 1.8 / 5 10 analysts
$78.64
$-4.81 (-5.76%)
Target: $97.30 (23.7%)

Price History

52-Week Range
Sign in to add TMDX to a watchlist or set price alerts.

Fundamentals

Market Cap$2.73B
P/E Ratio (TTM)20.37
Forward P/E34.42
EPS (TTM)$3.86
Dividend Yield-
Profit Margin22.69%
Revenue Growth20.70%
ROE36.29%
Debt/Equity167.50
Recommendation Buy 1.8
Analyst Target$97.30
Analysts10
Next Earnings Aug 4, 2026 AMC
Indexes Russell 2000

Technical Indicators

RSI (14)42.7
Beta1.88
SMA 20$85.69
SMA 40$87.27
52-Week High$156.00
52-Week Low$60.11
50-Day Avg$84.93
200-Day Avg$100.44
Avg Volume808.9K
Volume879.7K

Performance Analysis

BULLISH

TMDX shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 19% of its 52-week range.
~ RSI at 42.7 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Strong revenue growth of 20.7% year-over-year.
+ Healthy profit margin of 22.7%.
+ Wall Street consensus is "Buy" from 10 analysts.
+ Average analyst target of $97.30 implies 23.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report